Study of Lamotrigine 2×25 mg IR Tablets of Torrent Pharmaceuticals Limited, India and Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA, in Healthy Human Adult Subjects, Under Fasting Conditions.

Healthy Clinical Trial

Official title:

A Randomized, Open Label, Single Dose, Crossover, Bioequivalence Study of Lamotrigine 2×25 mg IR Tablets of Torrent Pharmaceuticals Limited., India and Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA, in Healthy Human Adult Subjects, Under Fasting Conditions.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00939614
• Other study ID #: 1086/06
• Status: Completed
• Phase: Phase 1
• First received: July 13, 2009
• Last updated: October 23, 2017

Study information

• Verified date: October 2017
• Source: Torrent Pharmaceuticals Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

• Objective:

• A randomized, open label, two treatment, two period, two sequence, single dose, crossover, bioequivalence study of Lamotrigine 2 x 25mg IR tablets of Torrent Pharmaceuticals Limited, India and Lamictal ® (Lamotrigine) 2 x 25 mg tablets of Glaxo-SmithKline, USA, in healthy human adult subjects, under fasting conditions.

• Study Design:

• Randomized, open label, two treatment, two period, two sequence, single dose, crossover, in 24+2 healthy human adult subjects to compare the single dose bioavailability of Torrent's Lamotrigine Tablets 2 × 25 mg and Lamictal® Tablets 2 × 25 mg of GlaxoSmithKline. Dosing periods were separated by a washout period of at least 21 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy adult subjects of either sex between 18-55 years of age (inclusive), having a body mass index (BMI) between 18 and 27 kg/m2.

• Subjects who have no evidence of underlying disease during screening and whose physical examination is performed within 21 days prior to commencement of the study.

• Subjects whose screening laboratory values are within normal limits or values outside normal limits considered by the physician/Principal Investigator to be of no clinical significance.

• Informed consent given in written form according to section 11.3 of the protocol.

• Female Subjects:

1. of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

2. postmenopausal for at least 1 year.

3. surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject).

Exclusion Criteria:

• Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.

• Alcohol dependence, alcohol abuse or drug abuse within past one year.

• Moderate to heavy smoking (> 10 cigarettes/day) or consumption of tobacco products.

• History of difficulty in swallowing tablet.

• Clinically significant illness within 4 weeks before the start of the study

• Asthma, urticaria or other allergic type reactions after taking any medication.

• Positive urine drug screening, HIV, Hepatitis B & C tests.

• Any history of hypersensitivity to Lamotrigine.

• Existence of any surgical or medical condition, which, in the judgment of clinical investigator might interfere with the pharmacokinetics of the drug or likely to compromise the safety of the subject.

• Inability to communicate or co-operate with the investigator due to language problem, attitude, poor mental development/impaired cerebral function.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Lamotrigine

Locations

Country	Name	City	State
India	Lotus Labs Pvt. Ltd.	Bangalore	Karnataka

Sponsors (1)

Lead Sponsor	Collaborator
Torrent Pharmaceuticals Limited

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bioequivalence